Adipogenic and Metabolic Effects of Antipsychotic Drugs

抗精神病药物的脂肪形成和代谢作用

• 批准号: 7806301
• 负责人: DAVID B ALLISON
• 金额: $ 5.5万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-08-01 至 2011-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7806301
• 关键词: Adverse effects; Antipsychotic Agents; Behavioral; Biochemical; Communities; Diabetes Mellitus; Discipline; Drug Prescriptions; Epidemiologist; Frequencies; Future; Health Care Costs; Metabolic; Metabolism; Molecular; Morbidity - disease rate; Obesity; Participant; Patients; Pharmaceutical Preparations; Prevention strategy; Quality of life; Research; Safety; Science; Scientist; Solutions; Stream; Therapeutic; Thinking; Translational Research; Treatment Efficacy; Videotape; Vulnerable Populations; Weight Gain; atypical antipsychotic; meetings; mortality; novel; patient population; prevent; public health relevance; symposium; treatment adherence; web site

DESCRIPTION (provided by applicant): Antipsychotic drugs (APDs), and atypical antipsychotic drugs in particular, are a therapeutic boon for many patients and are among the most widely prescribed drugs. Though possessing many advantages, many APDs have a major liability in their ability to promote adiposity, obesity, and metabolic dysregulation in an already metabolically vulnerable population. The past decade has been witness to substantial research effort aimed at quantifying, understanding, preventing, and alleviating these adverse effects. Specific Aim 1 of this meeting is to provide participants a thorough state of science uddate regarding: (a) The magnitude and frequency of obesity, diabetes, and other metabolic disturbances among patient populations that typically receive APDs; (b) The magnitude of the adverse metabolic effects by drug; (c) Biochemical and molecular mechanisms of these adverse APD effects; (d) The behavioral and energetic mechanisms of these adverse APD effects; (e) The safety and efficacy of treatment and prevention strategies to reduce these adverse effects; (f) The down-stream effects of these APDinduced alterations in adiposity and metabolism on morbidity, mortality, quality of life,treatment adherence, and health care costs; and; (g) The statistical and methodological issues involved. Specific Aim 2 is to promote new interdisciplinary and translational research by facilitating interactions among scientists from different disciplines and ranging from basic bench biologists to clinicians and epidemiologists. Specific Aim 3 is to make complete videotaped proceedings freely available to the worldwide community on our website. This 2-day meeting will bring together expert scientists from diverse disciplines to explore unanswered questions about these the metabolic and adipogenic effects of APDs and to introduce novel thoughts for future research. PUBLIC HEALTH RELEVANCE: Antipsychotic drugs are an important therapeutic option for many patients, but can cause serious weight gains, and metabolic disregulations. This conference will explore the reasons why and the potential solutions.

描述（由申请人提供）：抗精神病药（APD），特别是非典型抗精神病药，对许多患者来说是一种治疗福音，并且是最广泛处方的药物之一。尽管具有许多优点，但许多 APD 也有一个主要缺点，即它们能够促进本来就代谢脆弱的人群肥胖、肥胖和代谢失调。过去十年见证了旨在量化、理解、预防和减轻这些不利影响的大量研究工作。本次会议的具体目标 1 是向与会者提供关于以下方面的全面科学最新情况： (a) 通常接受 APD 的患者群体中肥胖、糖尿病和其他代谢紊乱的严重程度和频率； (b) 药物不良代谢作用的严重程度； (c) 这些 APD 不利影响的生化和分子机制； (d) 这些不利的 APD 影响的行为和能量机制； (e) 减少这些不利影响的治疗和预防策略的安全性和有效性； (f) 这些 APD 引起的肥胖和代谢变化对发病率、死亡率、生活质量、治疗依从性和医疗保健费用的下游影响；和; (g) 所涉及的统计和方法问题。具体目标 2 是通过促进不同学科科学家（从基础生物学家到临床医生和流行病学家）之间的互动，促进新的跨学科和转化研究。具体目标 3 是在我们的网站上向全球社区免费提供完整的录像会议记录。这次为期 2 天的会议将汇集来自不同学科的专家科学家，探讨有关 APD 的代谢和脂肪形成作用的尚未解答的问题，并为未来的研究引入新的想法。 公共卫生相关性：抗精神病药物是许多患者的重要治疗选择，但可能导致体重严重增加和代谢失调。本次会议将探讨其原因和潜在的解决方案。